News & Updates
Filter by Specialty:
Bimekizumab shows promise across the spectrum of axial spondyloarthritis
Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.
Bimekizumab shows promise across the spectrum of axial spondyloarthritis
18 Jun 2022
Antihistamines potentially beneficial for knee OA
The use of antihistamines was associated with reduced structural progression in knee osteoarthritis (OA), according to a post hoc analysis of two large phase III trials.
Antihistamines potentially beneficial for knee OA
17 Jun 2022
Familiarity with EuroLupus dosing for cSLE remains low despite uptick in use
Paediatric specialists now use low-dose EuroLupus cyclophosphamide (CYC) more than they did a decade ago in the treatment of childhood-onset systemic lupus erythematosus (cSLE), reports a study in North America. However, familiarity with EuroLupus dosing is still low.
Familiarity with EuroLupus dosing for cSLE remains low despite uptick in use
15 Jun 2022
Limited health literacy tied to low knowledge on SLE
Limited health literacy among patients with systemic lupus erythematosus (SLE) contributes to lower knowledge about the disease, a study has shown. The Lupus Knowledge Assessment Test (LKAT) may be improved and used as a screening tool to identify those with knowledge gaps.
